Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Research & Development (2016 - 2025)

Guided Therapeutics' Research & Development history spans 16 years, with the latest figure at $127000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 9.29% to $127000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $470000.0, a 10.82% decrease, with the full-year FY2025 number at $469000.0, down 10.84% from a year prior.
  • Research & Development hit $127000.0 in Q4 2025 for Guided Therapeutics, down from $136000.0 in the prior quarter.
  • Over the last five years, Research & Development for GTHP hit a ceiling of $222000.0 in Q2 2024 and a floor of $7000.0 in Q1 2023.
  • Historically, Research & Development has averaged $68550.0 across 5 years, with a median of $60000.0 in 2023.
  • The widest YoY moves for Research & Development: up 762.5% in 2023, down 66.67% in 2023.
  • Tracing GTHP's Research & Development over 5 years: stood at $17000.0 in 2021, then soared by 129.41% to $39000.0 in 2022, then soared by 120.51% to $86000.0 in 2023, then soared by 62.79% to $140000.0 in 2024, then dropped by 9.29% to $127000.0 in 2025.
  • Business Quant data shows Research & Development for GTHP at $127000.0 in Q4 2025, $136000.0 in Q3 2025, and $133000.0 in Q2 2025.